# A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

> **NCT04825743** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CeleCor Therapeutics** · enrollment: 2463 (actual)

## Conditions studied

- ST-elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** zalunfiban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04825743
- **Lead sponsor:** CeleCor Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-24
- **Primary completion:** 2026-05-13
- **Final completion:** 2026-05-13
- **Target enrollment:** 2463 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04825743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04825743, "A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04825743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*